Treatments
Asciminib and bosutinib were taken orally as tablets. Asciminib was taken in the fasted state (fasting for at least 2 h before and at least 1 h after taking asciminib; water was permitted); bosutinib was taken with food. Concomitant medications deemed necessary for the supportive care of patients were permitted. Treatment was continued for up to 96 weeks after the last patient received the first dose of study treatment or up to 48 weeks after the last bosutinib patient has switched to asciminib (whichever occurs last).